CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 19 enrolled
Drug / intervention
Intranasal Mupirocin and Topical Chlorhexidinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04218799
NCT04218799Phase 4Completed
CompareCT.gov

Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans

University of Maryland, Baltimore·interventional·Posted Jan 6, 2020·Updated Jun 6, 2023

In Brief

A Phase 4 clinical trial evaluating Intranasal Mupirocin and Topical Chlorhexidine for Human Microbiome. Completed, enrolled 19 participants across 2 sites.

Detailed Summary

The purpose of the research is to find out the effect of commonly used topical antibiotics on the bacteria that live in the nose, throat and on the skin of older adults. In addition, the investigators want to determine if these topical antibiotics affect how bacteria are spread in Community Living Centers of the VA Maryland Health Care System.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Microbiome
CountriesUnited States
CollaboratorsVA Office of Research and Development

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 6, 2020
Enrollment StartAug 12, 2014
Primary CompletionSep 22, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.5 years ago

Interventions

Intranasal Mupirocin and Topical Chlorhexidinedrug

Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.